Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interview: AC Immune CEO Reflects On Alzheimer's R&D Post-CREAD

Executive Summary

The recent failure of the CREAD studies to show a therapeutic effect for crenezumab in Alzheimer’s disease stunned developers. However, an ongoing clinical study of the MAb, and a series of other innovations being explored at Switzerland’s AC Immune, might still provide answers to this intractable condition.

You may also be interested in...



South Korea's ADEL Innovates With Anti-Tau Antibody For Alzheimer’s Disease

Emerging Company Profile: ADEL Inc. CEO Seung-Yong Yoon tells Scrip how its anti-tau antibody brings something different to the table in the challenging field of Alzheimer's disease and what's in store for the South Korean bioventure.

Rx Spending Growth To Be Driven By New Drug Entries, CMS Says

Advances in cancer, diabetes, and Alzheimer's could lead to expensive new treatments, contributing to spending increases in next decade, according to CMS projections.

AC Immune/Roche Drop Crenezumab After Phase III CREAD Alzheimer's Failure

Interim top-line data from CREAD 1 and 2 indicate crenezeumab is unlikely to meet its primary endpoints and the studies are being stopped, but a clinical study in Colombia in familial Alzheimer’s is set to continue.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006665

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel